Abstract
Hepatocellular carcinoma (HCC) is the most common subtype of liver cancer, and assessing its histopathological grade requires visual inspection by an experienced pathologist. In this study, the histopathological H&E images from the Genomic Data Commons Databases were used to train a neural network (inception V3) for automatic classification. According to the evaluation of our model by the Matthews correlation coefficient, the performance level was close to the ability of a 5-year experience pathologist, with 96.0% accuracy for benign and malignant classification, and 89.6% accuracy for well, moderate, and poor tumor differentiation. Furthermore, the model was trained to predict the ten most common and prognostic mutated genes in HCC. We found that four of them, including CTNNB1, FMN2, TP53, and ZFX4, could be predicted from histopathology images, with external AUCs from 0.71 to 0.89. The findings demonstrated that convolutional neural networks could be used to assist pathologists in the classification and detection of gene mutation in liver cancer.
Similar content being viewed by others
Introduction
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and is currently the main cause of liver-related death, leading to more than one million deaths annually worldwide1,2,3. Over several decades, substantial progress had been made in the understanding of HCC risk factors, epidemiology, and molecular pathogenesis. The early detection of HCC increases the chance of curative therapies in high overall survival. Unfortunately, most HCC patients are diagnosed at the intermediate to late-stage, which significantly decreases the overall survival4. Various predominant clinical risk factors for the development of HCC have been defined, including alcohol abuse, cirrhosis, metabolic syndrome, and hepatitis B and/or C virus infection5,6,7,8. However, multiple genetic alternation and signaling cascades also have a great influence on tumor progression and overall survival9.
The understanding of HCC molecular pathogenesis has been significantly improved over the past decade10. The development of genomic analysis has identified the major drivers that are responsible for cancer development and progression. HCC has been reported to have around 40 genomic aberrations, some of which are deemed as drivers. Several frequent HCC genomic alternations have been identified, including mutations in the CTNNB1 (β-catenin WNT pathway activation), TP53, telomere reverse transcriptase (telomere maintenance), AT-rich interaction domain 1A (ARID1A; chromatin remodeling), mammalian target of rapamycin signaling, RAS signaling, oxidative stress pathway activation, and aberrations in DNA methylation11. Previous studies have reported that the heterogeneity of HCC at both molecular and histological levels are correlated with gene mutations and oncogenic pathways12. The mutually exclusive CTNNB1 (40%) and TP53 (21%) mutations have been identified as two major groups of HCC according to its distinct phenotype. CTNNB1 mutated HCC is generally well-differentiated and large, with pseudoglandular and microtrabecular patterns, and lacks inflammatory infiltrates; whereas TP53 mutated HCC is generally poor-differentiated, with compact patterns, frequent vascular invasion, and pleomorphic, multinucleated cells13. The deeper understandings of the HCC phenotypes are essential for improving targeted therapies and clinical translation.
Pathologists could provide limited information regarding cancer reorganization from normal liver tissue and assess its histopathological grade via visual inspection, but it still lacks the underlying biological differences in HCC gene mutations associated with overall survival. The recent advances in artificial intelligence (AI) provided a novel way to assist clinicians to classify medical information and images14,15,4). Finally, the liver cancer tiles dataset consisted of four subsets, including the training, testing, internal validation, and external validation sets. The data in the training and internal validation cohorts from the Genomic Data Commons portal (https://portal.gdc.cancer.gov/) were publicly available without restriction, authentication or authorization. The independent external validation cohort we used consisted of slide images without identifiable information and all participants had provided written informed consent. Our study was approved by the SRRSH of Medicine Institutional Review Board (KY20181209-5).
Technical detail on frozen slides in the external validation cohort
The obtained specimens (e.g., liver tissues) were macroscopically examined, measured, sectioned through their longest axis, and then midsections were examined. The material was frozen at −28 °C, cut into 5–10 µm thick sections, Hematoxylin-Eosin (H&E) stained, and then analysed by pathologists with the light microscope. There were 67 out of 70 patients diagnosed as HCC and the related frozen slide were collected. Notably, normal liver tissues cannot be available in half of the obtained specimens, because normal liver tissues should be at least 2 cm away from tumors. Therefore, there were only 34 WSIs of normal liver tissues. In order to obtain digital pathology images, each slide was scanned at a magnification of 20× by using digital pathology scanner VS120 (Olympus).
Deep-learning with convolution neural networks
Typical convolutional neural networks contain several levels of convolution filters, pooling layers, and fully connected layers. In our study, we primarily used inception V3 architecture, which makes use of inception modules which are made from a spread of convolutions having different kernel sizes and a max-pooling layer. The initial five convolution nodes are combined with two max-pooling operations and followed by 11 stacks of inception modules. A fully connected layer to the end of the inception modules was then added to permit us to utilize the pre-trained model and finetune the parameters for our own task. Finally, a softmax layer was added as a classifier outputting a probability for every class, and the one with the highest probability was chosen as the predicted class.
We used the pre-trained model offered by TensorFlow and finetuned it using histopathological images. It was pre-trained on the ImageNet dataset and available at the TensorFlow-Slim image classification library (http://tensorflow.org). We initialized the parameters from the pre-trained model because pre-training can speed up the convergence of the network. Most importantly, it was difficult to train a deep network with a small number of images due to the massive number of network parameters.
Comparison with pathologists
One hundred and one WSIs of liver tissues without a label from the external validation cohort were used to test pathologist’s performance and compared with our model performance. All pathologists should report whether there is HCC, and if there is HCC, they should report histopathological grade via digital pathology images. The outcomes reported by six pathologists with 2-years, 5-years, and 10-years experience (two pathologists in each category) and our model were collected and analyzed by the R 3.6.0 (https://www.r-project.org). Cohen’s Kappa analysis was performed to assess inter-observer agreement. Good inter-operator agreements were observed in pathologists with 2-year experience (Kappa = 0.894; 95% CI, 0.837–0.944), pathologists with 5-year experience (Kappa = 0.933; 95% CI, 0.888–0.975), and pathologists with 5-year experience (Kappa = 0.967; 95% CI, 0.930–0.992).
Identification of significantly mutated genes
The gene mutation data for the matched patient sample were downloaded from the cancer genome atlas (TCGA). The gene mutated at least 10% of the available liver cancer samples were selected from the 283 cancer-related genes (Supplementary Fig. 2). The least absolute shrinkage and selection operator (LASSO) regression with a 10-fold cross-validation method was then performed to identify significant prognosis-related gene mutations by using R software packages (http://www.r-project.org). Finally, the ten most significant prognosis-related gene mutations, including ARID1A, ASH1L, CSMD1, CTNNB1, EYS, FMN2, MDM4, RB1, TP53, and ZFX4 were identified (Fig. 5).
a Selection of the super parameter λ in the LASSO model via 10-fold cross-validation based on the minimum standard. The optimal λ value of 0.122. b Shown here is a coefficient section view plotted against the log(λ) magnitude. The optimal λ corresponding to ten non-zero coefficients were obtained where the vertical line was drawn.
Training deep-learning network
Pathological diagnosis was the primary endpoint of interest for the classifier that recognizes tumors from normal liver tissue and the assessment of the histopathological grade. The status of gene mutation (mutation or wild type), based on the next-generation sequencing results, was the primary prerequisite in the classifier of mutation prediction. The model’s training strategy was based on an easy-to-use platform called EASY DL (https://ai.baidu.com/easydl/) that uses PaddlePaddle deep learning framework V3.0 created by Baidu Brain AI technology, inception V3 network developed by Google, and packaging code form Coudray20 and co-workers. The training set was used for training, and the testing set was used to evaluate the performances, finetune those parameters, and improve the models. A final model was selected according to the results of the testing set, where the F1-scores as a stop** rule. Notably, the subsets were grouped based on HCC patients rather than the WSIs. This method could maximize the size of the training set and avoid training and testing on tiles originating from the same human subjects. Thereby preventing the classifier from relying on intra-subject correlations between samples and resulting in inflated estimates of accuracy. In order to reduce selection bias, the performance of our model was then validated in the internal and external validation sets.
Statistical analysis
The ten most common and prognostic mutated genes were identified using the LASSO Cox regression model, and any differences of overall survival were evaluated by the Kaplan–Meier method with a log-rank test. The performance of those models was evaluated with F1-scores, MCC, and AUC. The F1-scores, ranging from 1 (perfect) to 0 (bad), is the harmonic average of the precision and recall21. MCC ranges from 1 (perfect) to −1 (bad). In addition, the probability of gene mutation was estimated and compared using the two-tailed Mann–Whitney U-tests. A P value of less than 0.05, was considered as statistical significance.
Data availability
The slide images and the corresponding cancer information were uploaded from the Genomic Data Commons portal (https://portal.gdc.cancer.gov/) and were in whole or in part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/). These data were publicly available without restriction, authentication, or authorization. The datasets for the independent cohorts generated and/or analyzed during the current study are available from the corresponding author (X.J.C.) upon reasonable request and through collaborative investigations.
Code availability
The codes that were used to train and validate the deep-learning model in the manuscript are available at https://github.com/drmaxchen-gbc/HCC-deep-learning. It also used other open-source codes (inception V3), which were available at https://github.com/openslide/openslide-python.
References
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. Cancer J. Clin. 69, 7–34 (2019).
Miller, K. D. et al. Cancer statistics for Hispanics/Latinos, 2018. Cancer J. Clin. 68, 425–445 (2018).
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68, 394–424 (2018).
Kudo, M. et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60, 1697–1707 (2014).
Sayiner, M., Golabi, P. & Younossi, Z. M. Disease burden of hepatocellular carcinoma: a global perspective. Dig. Dis. Sci. https://doi.org/10.1007/s10620-019-05537-2 (2019).
Chaturvedi, V. K. et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb. Pathog. 128, 184–194 (2019).
Torres, H. A. et al. The oncologic burden of hepatitis C virus infection: a clinical perspective. Cancer J. Clin. 67, 411–431 (2017).
Vandenbulcke, H. et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: a prospective study. J. Hepatol. 65, 543–551 (2016).
Rao, C. V., Asch, A. S. & Yamada, H. Y. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis 38, 2–11 (2017).
Juengpanich, S. et al. Role of cellular, molecular, and tumor microenvironment in hepatocellular carcinoma: possible targets and future directions in the Regorafenib Era. Int. J. Cancer. https://doi.org/10.1002/ijc.32970 (2020).
Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239 (2015).
Nault, J. C. & Villanueva, A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin. Cancer Res. 21, 1786–1788 (2015).
Calderaro, J. et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 67, 727–738 (2017).
Zhou, Q. et al. Grading of hepatocellular carcinoma using 3D SE-DenseNet in dynamic enhanced MR images. Comput. Biol. Med. 107, 47–57 (2019).
Weston, A. D. et al. Automated abdominal segmentation of CT scans for body composition analysis using deep learning. Radiology 290, 669–679 (2019).
Yi, F., Huang, J., Yang, L., **e, Y. & **ao, G. Automatic extraction of cell nuclei from H&E-stained histopathological images. J. Med. Imaging 4, 027502 (2017).
**ng, F., **e, Y. & Yang, L. An automatic learning-based framework for robust nucleus segmentation. IEEE Trans. Med. Imaging 35, 550–566 (2016).
Lin, H. et al. Automated classification of hepatocellular carcinoma differentiation using multiphoton microscopy and deep learning. J. Biophoton. https://doi.org/10.1002/jbio.201800435 (2019).
Li, S., Jiang, H. & Pang, W. Joint multiple fully connected convolutional neural network with extreme learning machine for hepatocellular carcinoma nuclei grading. Comput. Biol. Med. 84, 156–167 (2017).
Coudray, N. et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat. Med. 24, 1559–1567 (2018).
Darcy, A. M., Louie, A. K. & Roberts, L. W. Machine learning and the profession of medicine. JAMA 315, 551–552 (2016).
Skrede, O. J. et al. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet 395, 350–360 (2020).
Kather, J. N. et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat. Med. 25, 1054–1056 (2019).
Ehteshami Bejnordi, B. et al. Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies. Mod. Pathol. 31, 1502–1512 (2018).
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V. & Madabhushi, A. Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. Nat. Rev. Clin. Oncol. 16, 703–715 (2019).
Szegedy, C., Vanhoucke, V., Ioffe, S., Shlens, J. & Wojna, Z. Rethinking the Inception Architecture for Computer Vision. In Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition. 2818–2826 (2015).
Agarwal, R., Narayan, J., Bhattacharyya, A., Saraswat, M. & Tomar, A. K. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet 216–217, 37–51 (2017).
Zaman, G. J. R. et al. TTK inhibitors as a targeted therapy for CTNNB1 (beta-catenin) mutant cancers. Mol. Cancer Ther. 16, 2609–2617 (2017).
Liu, X., Liao, W., Yuan, Q., Ou, Y. & Huang, J. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. Oncotarget 6, 34309–34320 (2015).
Liang, X. D. et al. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma. PLoS ONE 9, e97739 (2014).
Dietz, R. L. & Pantanowitz, L. The future of anatomic pathology: deus ex machina? J. Med. Artif. Intell. 2, 4 (2019).
Tizhoosh, H. R. & Pantanowitz, L. Artificial intelligence and digital pathology: challenges and opportunities. J. Pathol. Inf. 9, 38 (2018).
Maddox, T. M., Rumsfeld, J. S. & Payne, P. R. O. Questions for artificial intelligence in health care. JAMA 321, 31–32 (2019).
Stead, W. W. Clinical implications and challenges of artificial intelligence and deep learning. JAMA 320, 1107–1108 (2018).
Acknowledgements
We would like to thank the EASY DL team and Hangzhou **xuan Health technology Co., Ltd. for their assistance in training our models. Thanks to Y.C., J.H.H., S.J.L., F.Y. and all our colleagues for their assistance in this study. This abstract of the study was presented at The International Liver Congress TM 2019 (EASL 2019) as Late-Breaker poster, in Vienna, Austria, on April 11–13, 2019. This work was supported by the Opening Fund of Engineering Research Center of Cognitive Healthcare of Zhejiang Province (No.2018KFJJ09), Zhejiang Medical Health Science and Technology Project (No.2016133597), and National Natural Science Foundation of China (No.81827804).
Author information
Authors and Affiliations
Contributions
M.Y.C., J.S.C., W.T., H.Y., and B.Z. were involved in the study design, data collection and analysis, and drafted the paper; H.P.Z., S.J., and Q.J.M. collected and checked data; M.Y.C., J.S.C., X.J.C., and W.T. revised the paper; X.J.C. designed, supervised the study; and all authors wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, M., Zhang, B., Topatana, W. et al. Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning. npj Precis. Onc. 4, 14 (2020). https://doi.org/10.1038/s41698-020-0120-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41698-020-0120-3
- Springer Nature Limited
This article is cited by
-
Unified deep learning models for enhanced lung cancer prediction with ResNet-50–101 and EfficientNet-B3 using DICOM images
BMC Medical Imaging (2024)
-
Evolution of LiverNet 2.x: Architectures for automated liver cancer grade classification from H&E stained liver histopathological images
Multimedia Tools and Applications (2024)
-
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics
Nature Cancer (2024)
-
Biased data, biased AI: deep networks predict the acquisition site of TCGA images
Diagnostic Pathology (2023)
-
Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status
Scientific Reports (2023)